Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary refractory Hodgkin's disease

S J Horning1

  • 1Stanford University, CA, USA.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|February 2, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introduction: ASCO-ESMO consensus statement on quality cancer care.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by <sup>90</sup>Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499.

Leukemia·2016
Same author

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Patients with primary refractory Hodgkin

Area of Science:

  • Hematology
  • Oncology
  • Clinical Medicine

Background:

  • Primary refractory Hodgkin's disease is defined by disease progression or inadequate response to initial treatment.
  • Current salvage chemotherapy offers poor long-term survival rates (<10% at 10 years).

Purpose of the Study:

  • To review treatment strategies for primary refractory Hodgkin's disease.
  • To identify promising approaches for improving cure rates in this patient subset.

Main Methods:

  • Review of existing literature on refractory Hodgkin's disease treatments.
  • Analysis of outcomes associated with myeloablative therapy and autografting.
  • Consideration of salvage radiotherapy in conjunction with transplantation.

Main Results:

Related Experiment Videos

  • Myeloablative therapy and autografting show improved outcomes compared to salvage chemotherapy.
  • Projected event-free survivals with these methods range from 18%-49% at four years.
  • Salvage radiotherapy may benefit selected patients, particularly when combined with transplantation.

Conclusions:

  • Early identification of patients at high risk for induction failure is crucial.
  • Modifying primary treatment based on risk stratification holds significant promise for improving cure rates.
  • Multimodality approaches, including transplantation, are key for managing refractory disease.